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The amplitude of the P300 event-related potential (ERP) has been reported to be reduced over left compared to right temporal
sites in schizophrenia patients. This left temporal P300 reduction has been associated with positive symptom severity and gray
matter reduction in the left superior temporal gyrus. We investigated a group of patients with a first episode of schizophrenia
spectrum psychosis and a group of normal controls to verify if P300 amplitude asymmetry already exists around the time of
presentation for treatment. Relative to normal control subjects, no P300 asymmetry was found in patients. Nevertheless, P300
asymmetry was correlated with the severity of positive symptoms and worse global functioning (GAF), a good predictor of poor
outcome.
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The amplitude of the P300 event-related potential
(ERP) is consistently reduced over midline electrodes,
not only in schizophrenia patients (reviewed in Ford,
1999), their relatives (Bharath et al., 2000), subjects at
high risk for schizophrenia (van der Stelt et al., 2005)
and patients having suffered from a first-episode of⁎ Corresponding author. Douglas Mental Health University Institute,
F. B. Common Pavilion, 6875 Boul. LaSalle, Montréal, Québec,
Canada, H4H 1R3. Tel.: +1 514 761 6131 #3405; fax: +1 514 888 4099.
E-mail address: bruno.debruille@douglas.mcgill.ca
(J.B. Debruille).
0920-9964/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.schres.2007.03.024schizophrenia (Hirayasu et al., 1998; Salisbury et al.,
1998; Brown et al., 2002; McCarley et al., 2002) but
also in patients with an affective psychosis (Salisbury
et al., 1999; O'Donnell et al., 2004) and in several other
diseases compared to normal controls (Ford, 1999).
On the other hand, a P300 amplitude asymmetry has
been described in schizophrenia patients, with a greater
amplitude reduction over the left than the right temporal
lobe (e.g., Morstyn et al., 1983; Faux et al., 1988). In
contrast with the above mentioned midline P300, this left
temporal P300 abnormality has not been observed in
affective psychosis patients (Salisbury et al., 1999) or in
other diseases so far, and has been shown to be strongly
correlated with the severity of positive symptoms
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al., 2005) including thought disorder (Meisenzahl et al.,
2004; Kirihara et al., 2005). Interestingly, recent studies
suggest that P300 asymmetry may increase with the
progression of the disease. It is absent in subjects at high
imminent risk for schizophrenia and is found to be more
prominent in chronic than in recent-onset patients (van der
Stelt et al., 2005). As well, older chronic patients (mean
age 32.8 years) but not younger individuals (mean age
26.8) were found to have a reduced left temporal P300
(Iwanami et al. 2002). As to studies of patients having
suffered from a first-episode of psychosis (FEP), two did
report a greater reduction of P300 over the left than the
right temporal lobe (Salisbury et al., 1998; McCarley et
al., 2002), whereas others, like Hirayasu et al. (1998), did
not describe this asymmetry. Interestingly, the mean age
of the patients of the latter study was close to that of the
younger patients of Iwanami et al. (2002), whereas, in the
two FEP studies that reported P300 asymmetry (Salisbury
et al., 1998; McCarley et al., 2002), mean age was clearly
greater. Thus, it is possible that the asymmetry develops,
or is detectable, only after having experienced symptoms
of schizophrenia for a relatively longer period of time.
The objectives of the present study were thus: a) to
assess if persons suffering from a first episode of
previously untreated psychosis in early adulthood show
evidence of temporal P300 asymmetry around the time of
entry to treatment; b) to study the correlation between
P300 asymmetry and the severity of positive symptoms in
these patients; and c) to examine any relationship between
P300 asymmetry and the duration of untreated illness/
psychosis, the quality of the premorbid adjustment and the
age of the patients at the time of ERP recordings.
2. Methods
2.1. Participants
Forty four patients presenting with a first episode of a
psychotic disorder (mean age: 22.6±3.6) for treatment
to the Prevention and Early Intervention for Psychoses
Program (PEPP-Montreal) signed an informed consent
and were recruited for this study. The PEPP program has
been designed to provide early assessment and treatment
for adolescents and young adults (ages 14–30), who
either have never been treated, or have received no more
than one month of treatment with an antipsychotic
medication. Patients' diagnosis was confirmed through
administration of a Structured Clinical Interview for
DSM-IV (SCID-IV) within a month of admission to the
program (First et al., 1995). Based on the SCID-IV, 27
patients had a diagnosis of a schizophrenia spectrumpsychosis (i.e., 19 schizophrenia, 3 schizophreniform
and 5 schizoaffective disorder) and 17 patients had other
psychotic disorders (4 affective psychosis, 2 delusional
disorder, and 11 psychosis not otherwise specified
(NOS)). Although, delusional disorder or psychosis
NOS is sometimes included in schizophrenia spectrum
psychosis (e.g., Franzek and Beckmann, 1998), a
smaller proportion of patients in these categories
maintain the same diagnosis at follow-up evaluations.
Whereas, the schizophrenia spectrum diagnosis restrict-
ed to schizophrenia, schizophreniform and schizoaffec-
tive disorder has average rates of consistency of 90%
(Schwartz et al., 2000; Veen et al., 2004), psychosis
NOS is associated with approximately 45 to 50%
consistency (Schwartz et al., 2000; Schimmelmann
et al., 2005) and delusional disorder with more varying
rates (e.g., about 67% in Schwartz et al., 2000; about
87% in Schimmelmann et al., 2005). We thus decided to
exclude these two last categories from our group of
patients with a first episode of schizophrenia spectrum
psychosis (FEP-S). Among the 27 remaining patients
(mean age at the time of ERP recordings: 22±3), 11
were taking olanzapine (mean dose: 11.36 mg±7.36), 6
risperidone (mean dose: 1.50 mg± .84), 2 quetiapine
(mean dose: 150 mg±70.71), 1 loxapine (dose: 75 mg)
and 7 were not medicated at the time of ERP recordings.
All were right-handed. Scores on Global Assessment of
Functioning (GAF) were obtained based on ratings
conducted at the time of the first assessment. Patients
were administered a semi-structured interview schedule,
the Circumstances of Onset and Relapse Schedule
(Norman et al., 2004; Malla et al., 2006), to provide
estimates of the time of onset of psychosis, of the
duration of untreated psychosis (DUP) and of the
duration of untreated illness (DUI). DUP was defined as
the period between the time of onset of psychotic
symptoms and the commencement of adequate treatment
(taking anti-psychotic medication for a period of one
month or until significant response, which ever came
first). DUI corresponded to the length of time between
the onset of any psychiatric symptoms and the initiation
of antipsychotic therapy. Based on 20 randomly selected
cases of FEP in our program, a relatively high degree of
agreement was achieved on estimation of DUP between
three raters (ICC ranging from .86 to .98). Pre-morbid
adjustment was assessed with the Pre-morbid Adjust-
ment Scale (PAS; Cannon-Spoor et al., 1982). It included
2 sections: the PAS-1 for childhood (5 to11 years of age)
and the PAS-2 for early adolescence (12 to 15).
A group of healthy right-handed subjects (n=14)
matched for mean age (24 years±4) and gender (11
males/3 females) was also recruited. Control subjects had
Table 1
Demographic and clinical variables for all subjects









Age 22 (±3) 22 (17–28) 24 (±4) 25 (18–30)
Gender 21m/6f 11m/3f
Medication 172 (±181) 125 (0–750) – –
DUP 32 (±39) 16 (1–152) – –
DUI 190 (±217) 120 (15–898) – –
PAS 1 .2 (±.1) .1 (0–.4) – –
PAS 2 .3 (±.1) .3 (.1–.4) – –
GAF 41 (± 9) 42 (24–58) – –
SAPT 20 (±17) 16 (0–53) – –
RDT 14 (±12) 11 (0–39) – –
DZT 6 (±7) 5 (0–26) – –
Acronym meanings: FEP-S: patients suffering from a first episode of a
schizophrenia spectrum psychosis. Ctrl: control subjects. Medication:
medication dose in chlorpromazine equivalents (for more details see
Methods section); DUP: duration of untreated psychosis in weeks;
DUI: duration of untreated illness in weeks; PAS: quality of the
premorbid adjustment, PAS 1: during childhood (5–11), PAS 2: during
early adolescence (age 12–15), values of PAS range from 0 to 1, with 0
representing the best premorbid adjustment; GAF: Global Assessment
of Functioning; SAPT: Total score for positive symptoms; RDT: Total
score for reality distortion; DZT: Total score for disorganization.
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in which theywere asked if themselves or one of their first
degree relatives ever had a psychological problem. They
were also asked whether they were previously hospital-
ized and whether they had already taken medication for
psychiatric reasons. Finally, the presence of any history of
head injury with loss of consciousness longer than 5 min,
or of epilepsy crises was inquired. Subjects answering
positively to one of these questions were excluded. It was
also possible to exclude all potential participants who
were using illegal drugs except for a few cannabis users
but all participants agreed not to take cannabis or alcohol
the day before or the day of the recording. All subjects
signed an informed consent form accepted by the Douglas
hospital research ethics board.
2.2. Symptom evaluation
Patients were evaluated with the Scale for the
Assessment of Positive Symptoms (SAPS) (Andreasen,
1984) and the Scale for the Assessment of Negative
Symptoms (SANS) (Andreasen, 1983). Total scores
(SAPT) were computed for positive symptoms. Scores
were obtained for reality distortion (RDT) by adding
respective scores for items of the hallucination and
delusion sub-scales, and for disorganization (DZT) by
adding the scores for positive formal thought disorder and
bizarre behavior of the SAPS and inappropriate affect
item of the SANS (Andreasen et al., 1995) (Table 1).
2.3. Oddball task
All subjects performed an auditory oddball task. Target
and non-target stimuli were delivered randomly. The
target was a 2000Hz tone presented 20% of the trials. The
non-target was a 1000Hz tone presented 80% of the trials.
Both tones were delivered binaurally at a 70 dB sound
pressure level for 100 ms with a rise/fall time of 10 ms.
Adjacent stimuli were separated by a 1440 ms interstim-
ulus time. There were 4 blocks containing 150 stimuli
each and separated by 5 min intervals. In each block,
subjects had to mentally count the number of times the
target tone was presented and to keep their eyes open
(Debruille et al., 2005). After each block, subjects were
asked how many stimuli they had counted. Target count
accuracy was computed as the difference between the
correct number and the number each subject gave.
2.4. ERP recordings
All patients were recorded at an interval less than, or
equal to, 2 weeks from their clinical evaluation. Scalpencephalogram (EEG) was recorded at 5 electrode sites
(Fz, Pz, Cz, T3 and T4) placed according to the
international expanded 10–20 system (Electrode nomen-
clature committee, 1991), using the right earlobe as a
reference. Eye movements and blinks were controlled by
F7 and F8 for horizontal movements and by FP2 and an
additional electrode placed on the right cheek for vertical
movements. The impedance of the electrodes was kept
below 5 kΩ. The EEG was amplified 20,000 times by
Contact Precision amplifiers. High- and low-pass filter
half-amplitude cut-offswere set at .01 and 100Hz,with an
additional 60 Hz electronic notch filter. Signals were
digitized on-line at a sampling rate of 256 Hz and stored
along with stimulus and response codes for subsequent
averaging using the Instep (version 4.3) software package.
EEG epochs contaminated by eyes movements, excessive
myogram, amplifier saturations or analog to digital
clipping were removed offline with automatic rejection
criteria: trials for which analog to digital clipping
exceeded 100 ms, and electrodes for which amplitude
exceeded ±100 μV were excluded from averaging.
Target ERPs were computed by averaging 1000 ms
epochs for each electrode starting 200 ms before the
onset of the stimulus. The latency of the peak of the
positive deflection occurring between 200 and 500 ms
was determined for each group grand average. For all
Fig. 1. Grand average of the target event-related potentials (ERPs) for
each group. Solid lines are for patients with a first episode of
schizophrenia spectrum psychosis (FEP-S). Dashed lines are for
normal controls. All subjects performed an auditory oddball task.
Target and non-target stimuli were delivered randomly. The target was
a 2000 Hz tone presented 20% of the trials. The non-target was a
1000 Hz tone presented 80% of the trials.
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groups, P300 peaked between 300 and 400 ms. More
precisely, the electrode site at which the P300 had the
earliest maximum was Cz (312 ms for FEP-S and 331
for the controls), while the latest maximum was found
on T3 (370 ms for FEP-S and 366 for the controls) for
both groups. Therefore, mean P300 voltage amplitudes
were computed in a 300 to 400 ms time window relative
to the −200 to 0 ms baseline.
Meanwhile, the latencies of the P300s were measured
in each subject by assessing the times of the maximum
of the positive peak observed between 200 and 500 ms.
This was done after smoothing the curves so that only 1
positive peak appeared in the 200–500 window.
2.5. Data analyses
Three mixed-model repeated-measure ANOVAs
were used with group (controls vs. FEP patients) as the
between subject factor. For the study of P300 latency, the
electrode factor was used as within subject factor. It had
five levels, frontal (Fz), central (Cz), parietal (Pz), left
(T3) and right mid-temporal (T4). For the study of P300
amplitude, one ANOVAwas run with anterior–posterior
site (Fz vs. Cz vs. Pz) as within subject factor to
investigate midline P300 amplitude, and the other
ANOVA with laterality (T3 vs. T4) to investigate P300
asymmetry. To avoid confounding effects that could be
generated by global between group differences as to their
P300 amplitudes, all lateral analyses were conducted on
normalized mean amplitudes, that is by dividing
amplitudes at T3 and at T4 by the mean amplitude
observed at Cz, as in Salisbury et al. (1998).
Pearson's correlations (r) were calculated in patients
between clinical variables and the mean amplitude of
P300 at the left temporal site (T3), and between clinical
variables and P300 asymmetry, as measured by the
subtraction of the amplitude of the P300 at the left
temporal site from the amplitude of the P300 at the right
temporal site (T4–T3).
For the figures, the ERP waveforms were smoothed
to remove high frequency noise. This was done by
simple averaging of groups of 3 consecutive points 5
times using the Instep software package (version 4.3).
3. Results
3.1. Target count accuracy
The FEP group performed less well (mean accuracy
rate 95%) than the control group (98%) but this
difference was not significant [F(1,39)=1.75, p=.19].3.2. P300 latency
The ANOVA on P300 latency revealed no between-
group difference in P300 latency [F(1,39) = .11,
p= .92], nor any interaction between group and
electrodes [F(4,156)= .53, p= .66] (see Fig. 1).
3.3. Midline P300 amplitude
Mean P300 amplitudes were maximal at Pz for both
groups (10.08 μV±3.36 in controls; 5.66 μV±2.48 in FEP
patients). The ANOVA performed with midline site
measures showed that P300 amplitudes were generally
greater in the control group than in the FEP group
[F(1,39)=23.8, pb .001] (see Fig. 1). The group
difference was significantly larger at Cz than at other
electrode sites [F(2,78)=13.63, p≪ .001]. Post-hoc
analysis for each electrode site revealed that P300
Table 2
Pearson correlation (r) between mean amplitude of the P300 at the left
temporal site (T3) and clinical variables, and between P300 asymmetry
(T4–T3) and the same variables in FEP-S patients
T3 T4–T3
r p r p
Age − .13 .52 +.03 .86
Sex +.03 .88 +.05 .80
Medication − .26 .20 − .06 .78
DUP − .15 .48 +.32 .07
DUI − .20 .35 +.18 .39
PAS 1 +.03 .88 +.11 .62
PAS 2 − .11 .60 +.16 .45
GAF +.15 .23 − .33 .04
SAPT − .01 .48 +.47 .01
RDT − .09 .31 +.40 .02
DZT − .15 .23 +.44 .01
p values are given for one-tailed tests of significance for positive
symptoms scores and GAF for which there were a priori hypotheses.
Two-tailed tests of significance were used for all other variables. T3:
Mean amplitude of the P300 at left temporal site. T4–T3: Subtraction
of the mean amplitude of the P300 at the left temporal site (T3) from
the mean amplitude of the P300 at the right temporal site (T4). Sex:
1=male; 2=female. See Table 1 legend for all other demographic and
clinical variables' acronyms.
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FEP-S at Fz [F(1,40)=12.87, p=.001], Cz [F(1,40)=
25.36, p≪ .001] and Pz [F(1,40)=25.27, p≪ .001].
3.4. Asymmetry in P300 amplitude over temporal sites
(T3 and T4)
Mean normalized T4–T3 amplitude differences were
.13 (±.21) in control subjects and .19 (±.58) in FEP
patients. The ANOVA performed with lateral site
measures did not reveal any significant interaction
between laterality and group [F(1,39)= .16, p=.69],
showing that P300 was not at all more asymmetrical in
the patients' groups than in the control group.1
There was no significant correlation between P300
asymmetry and age, sex, medication dose, DUI or PAS
in the patients' group (Table 2). However P3001 Because the activity of the reference site is eliminated by the
subtraction, the exact placement of the reference site has no
importance for such analysis (Hagemann et al., 2001). The same
analysis with ERPs obtained with an averaged reference instead of a
right earlobe reference was also associated with an absence of
interaction between laterality and group: [F(1,39)= .75, p=.39]. The
similarity between the two analyses is further illustrated by the fact
that when voltage amplitudes obtained with an average reference were
normalized with the original Cz values (right earlobe reference)
instead of their respective Cz values, the statistical results of the
ANOVA were identical: [F(1,39)= .16, p=.69].asymmetry was negatively correlated with global
assessment of functioning score (GAF), and positively
correlated with the total scores of positive symptoms
(SAPT, RDT, and DZT). Moreover, there was a trend for
more asymmetric patients to have a longer duration of
untreated psychosis (DUP) (see Table 2).
3.5. Left temporal P300 amplitude (T3)
There was no significant correlation between the
amplitude of the P300 at the left temporal site and age,
sex, medication dose, DUP, DUI, PAS, global assess-
ment of functioning (GAF) or symptoms' scores in FEP
patients (see Table 2).
4. Discussion
The present study confirmed a general decrease in
midline P300 amplitude in patients with a first episode
of schizophrenia spectrum psychosis (FEP-S) relative to
normal controls. However, no P300 asymmetry was
found, nor was there any correlation observed between
left temporal P300 amplitude and severity of symptoms.
Nevertheless, higher levels of positive symptoms were
associated with greater P300 asymmetry (the subtraction
of the amplitude of the P300 at the left temporal site
from the amplitude of the P300 at the right temporal
site). Moreover, greater P300 asymmetry was associated
with worse global functioning scores (GAF) and
showed a tendency to be associated with longer DUP.
The substantial reduction inmidline P300 amplitude in
FEP-S patients relative to normal controls confirms
previous findings (e.g., Salisbury et al. 1998; McCarley
et al. 2002). However, this reduction appears to be of
greater magnitude in the present study: P300 peak
amplitudes in FEP-S patients were about half of that
found by Salisbury et al. (1998), and one third of that
found by McCarley et al. (2002). In addition to the
differences between the experimental protocols used, a
possible explanation for this discrepancy ismedication. In
Salisbury et al. (1998) and in McCarley et al. (2002),
patients weremoremedicated, withmean chlorpromazine
equivalent doses of 239.6 and 262.7 mg respectively
compared to 172mg in the present study. Moreover, FEP-
S patients in McCarley et al. (2002) had been medicated
for a longer time (158.9 days on average) before
admission, while the criteria for inclusion in the present
study was antipsychotic medication of no more than
30 days duration. Although general amplitude reduction
has been shown to be present in non-medicated first-
episode patients (Hirayasu et al., 1998; Demiralp et al.,
2002), P300 amplitude may be substantially increased by
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Gonul et al., 2003; Wang et al., 2005). Differences in
treatment could thus account for the larger P300
amplitudes observed in the aforementioned studies
compared to the present study.
We failed to observe a greater P300 asymmetry over
temporal sites in FEP-S patients compared to control
subjects. This absence of significant asymmetry differ-
ence cannot be explained by the importance of the general
amplitude reduction in patients as several studies have
demonstrated that general low P300 amplitudes were
associated with more asymmetry (Strik et al., 1994; Hill
and Weisbrod, 1999; Iwanami et al., 2002). Meanwhile,
we found that P300 amplitude asymmetry was positively
correlated with the severity of positive symptoms.
Moreover, asymmetry was negatively correlated with
global functioning score (GAF) and showed a trend to be
positively correlated with longer duration of untreated
psychosis (DUP). These results are consistent with the
anatomical substrates assumed to be involved in the
temporal P300. Indeed, greater volume reduction of the
temporal gray matter has been found in patients having
more severe clinical symptoms and in those with longer
DUPs (Barta et al., 1990; Shenton et al., 1992; and for
DUPs: Lappin et al., 2006). P300 asymmetry may thus be
present only in subgroups of patients, having more severe
clinical symptoms and possibly suffering from related
reduction in gray matter (Ford et al., 2000). However, the
relatively small sample size and limited variance in DUP
may have led to insufficient power to detect significant
correlations between P300 asymmetry and DUP.
Alternatively, our findings of an absence of greater
P300 asymmetry relative to normal controls in a group
of young FEP-S patients with globally short DUPs (the
median DUP was 16 weeks in these patients) may be
taken with other data to suggest that left temporal P300
deficits in schizophrenia would be progressive. Indeed,
these deficits are absent in subjects at high imminent
risk for schizophrenia and are found to be more
prominent in chronic than in recent-onset patients (van
der Stelt et al., 2005). P300 asymmetry may thus appear
after what is referred to as a ‘critical period’ in the course
of schizophrenia, that is approximately the first 3 years
following onset of the first episode where psychological
and biological plasticity are maximum (Birchwood
et al., 1998).
While the delay after the onset of the first symptoms
could thus be of critical importance, patients' age at the
time of the assessment could also be relevant (Iwanami
et al., 2002). The superior temporal gyrus (STG), to
which P300 has been associated (e.g., Knight et al.,
1989), is one of the last brain regions to mature. Indeed,the physiological decrease in gray matter in this area
seems to start close to 20 years of age in normal subjects
(Lenroot and Giedd, 2006; Giedd et al., 1999). It is
possible that a left-sided increase in gray matter loss
would begin during this same period in schizophrenia. A
recent MRI study in young offspring of patients with
schizophrenia (mean age: 14.9 years) did not find a left
sided asymmetry in the STG, even if general gray matter
decrease was observed in these subjects at risk for
schizophrenia compared to normal controls (Rajarethi-
nam et al., 2004). Although gray matter reduction was
shown to be progressive in the left STG in FEP patients
(Kasai et al., 2003), no study to our knowledge
investigated groups of patients with mean ages less
than 25 years. Accordingly, the young age of our
patients by itself could explain why no P300 asymmetry
was found in the present study whereas it was reported
along with a left STG volume reduction in 2 other
studies (Salisbury et al. 1998; McCarley et al. 2002).
In conclusion, despite the absence of a greater P300
asymmetry in patients with a first episode of schizophrenia
spectrum psychosis than in normal controls, we observed a
positive correlation between the magnitude of this
asymmetry and positive symptom severity. Also, P300
asymmetry was correlated with worse global functioning,
a good predictor of poor outcome. Longitudinal studies of
patients in the early stages of their illness would be helpful
to track the progress of the asymmetry in individual cases
and test if it is a good predictor of the outcome.
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